PDSB - PDS Biotech gains after updates on pivotal trial for lead asset
2023-08-14 09:26:13 ET
More on PDS Biotech
- PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
- The Prognosis For PDS Biotechnology
- PDS Biotechnology: Promising Interim HNSCC Data Reaffirms Investment Prospects
- PDS Biotech meets efficacy threshold in mid-stage trial for head and neck cancer therapy
- PDS Biotech defended on Wall Street after selloff
- PDS Biotech gains 20% after Phase 2 data for lead asset in head and neck cancer
For further details see:
PDS Biotech gains after updates on pivotal trial for lead asset